*[[ICD]] implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD (Sudden Cardiac Death), or undiagnosed syncope when [[Ventricular Tachycardia|ventricular tachycardia]] or [[Ventricular Fibrillation|ventricular Fibrillation]] has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y.
*[[ICD]] implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD (Sudden Cardiac Death), or undiagnosed syncope when [[Ventricular Tachycardia|ventricular tachycardia]] or [[Ventricular Fibrillation|ventricular Fibrillation]] has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y.
*Radiofrequency [[ablation]] can be useful as adjunctive therapy in management of patients with ARVC with recurrent [[Ventricular Tachycardia|ventricular tachycardia]], despite optimal antiarrhythmic drug therapy.
*Radiofrequency [[ablation]] can be useful as adjunctive therapy in management of patients with ARVC with recurrent [[Ventricular Tachycardia|ventricular tachycardia]], despite optimal antiarrhythmic drug therapy.
== ECG in ARVD==
On [http://www.arvd.org ARVD.org] the latest ECG criteria for ARVD are updated. To enhance detection of ECG abnormalities specific settings to record an ARVD ECG can be used: [http://arvd.org/ECG.pdf ECG settings to enhance recording of Epsilon waves].
<gallery>
In patients suspected to have ARVD both a normal 12 lead ECG and a Signal Averaged ECG ([[SAECG]]) are useful.
ECG with an epsilon wave in V1 A section throughout the heart of an ARVC patient. (A) Transmural fatty replacement of the right ventricular free wall. (B) Myocardial atrophy is confined to the right ventricle and substantially spares the interventricular septum as well as the left ventricular free wall. Corrado Reproduced with permission from BMJ Publishing Group Ltd.
Arrhythmogenic Right Ventricular Cardiomyopathy, (ARVC, or ARVD: Arrhythmogenic Right Ventricular Disease) is characterized by fatty replacement and fibrosis of the heart. Most commonly the right ventricle apex and outflow tract are involved. However the left ventricle can be affected to.Corr
As a result of the fatty replacement and fibrosis, ventricular arrhythmias are common in this disease and can lead to palpitations, syncope and sudden death. At more advanced ages right ventricular pump failure can occur.
The diagnosis is based on major and minor criteria, as published by the European Society of Cardiology.McKenna1994
ARVC is a progressive disease. The incidence is estimated to be 1:3.000-1:10.000. Manifestations are usually seen in teenagers. Although the diagnosis is more often made in athletes, sports are not thought to have a causative relationship with the disease. ARVD can occur in families; more than 9 different chromosomal defects have been described, most often with autosomal dominant inheritance.
One unique form of ARVD, called Naxos disease (after the Greek island where it was first diagnosed), has an autosomal recessive pattern of inheritance.
Diagnosis ARVC is a difficult diagnosis to make. Therefore, the European Society of Cardiology has created a list of diagnostic criteria for the diagnosis of ARVC#McKenna1994 (see table).
Major diagnostic criteria for Arrhythmogenic Right Ventricular CardiomyopathyMcKenna1994
Familial disease confirmed at necroscopy or surgery
Severe dilatation and reduction of right ventricular ejection fraction with no (or only mild) LV impairment
Localized right ventricular aneurysms (akinetic or diskinetic areas with diastolic bulging)
Severe segmental dilataion of the right ventricle
Fibrofatty replacement of myocardium on endomyocardial biopsy
Diagnostic criteria that can be diagnosed on the ECG
(major) Epsilon wave or localized prolongation (>110ms) of the QRS complex in right precordial leads (V1-V3)
(minor) Inverted T waves in right precordial leads (V2 and V3) (people aged more than 12 yr; in absence of RBBB
In 2009 these criteria were updatedcoxCrit2010, see the table below.
Treatment focuses on avoiding complications.ACC2006
Medication:
Anti-arrhythmics: Sotalol better than Amiodarone.
ACE-inhibitors to prevent cardiac remodelling
ICD implantation is recommended for the prevention of sudden cardiac death in patients with ARVC with documented sustained VT or VF who are receiving chronic optimal medical therapy.
ICD implantation can be considered for the prevention of sudden cardiac death in patients with ARVC with extensive disease, including those with left ventricular involvement, 1 or more affected family member with SCD (Sudden Cardiac Death), or undiagnosed syncope when ventricular tachycardia or ventricular Fibrillation has not been excluded as the cause of syncope, who are receiving chronic optimal medical therapy, and who have reasonable expectation of survival with a good functional status for more than 1 y.
Radiofrequency ablation can be useful as adjunctive therapy in management of patients with ARVC with recurrent ventricular tachycardia, despite optimal antiarrhythmic drug therapy.
In patients suspected to have ARVD both a normal 12 lead ECG and a Signal Averaged ECG (SAECG) are useful.
Revised Task Force Criteria ARVD / ARVC
Comparison of Original and Revised Task Force Criteria
Original Task Force Criteria
Revised Task Force Criteria
I. Global or regional dysfunction and structural alterations∗
Major
Severe dilatation and reduction of RV ejection fraction with no (or only mild) LV impairment
Localized RV aneurysms (akinetic or dyskinetic areas with diastolic bulging)
Severe segmental dilatation of the RV
By 2D echo:
Regional RV akinesia, dyskinesia, or aneurysm
and 1 of the following (end diastole):
PLAX RVOT ≥32 mm (corrected for body size [PLAX/BSA] ≥19 mm/m2)
PSAX RVOT ≥36 mm (corrected for body size [PSAX/BSA] ≥21 mm/m2)
or fractional area change ≤33%
By MRI:
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
and 1 of the following:
Ratio of RV end-diastolic volume to BSA ≥110 mL/m2 (male) or ≥100 mL/m2 (female)
or RV ejection fraction ≤40%
By RV angiography:
Regional RV akinesia, dyskinesia, or aneurysm
Minor
Mild global RV dilatation and/or ejection fraction reduction with normal LV
Mild segmental dilatation of the RV
Regional RV hypokinesia
By 2D echo:
Regional RV akinesia or dyskinesia
and 1 of the following (end diastole):
PLAX RVOT ≥29 to <32 mm (corrected for body size [PLAX/BSA] ≥16 to <19 mm/m2)
PSAX RVOT ≥32 to <36 mm (corrected for body size [PSAX/BSA] ≥18 to <21 mm/m2)
or fractional area change >33% to ≤40%
By MRI:
Regional RV akinesia or dyskinesia or dyssynchronous RV contraction
and 1 of the following:
Ratio of RV end-diastolic volume to BSA ≥100 to <110 mL/m2 (male) or ≥90 to <100 mL/m2 (female)
or RV ejection fraction >40% to ≤45%
II. Tissue characterization of wall
Major
Fibrofatty replacement of myocardium on endomyocardial biopsy
Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
Minor
Residual myocytes 60% to 75% by morphometric analysis (or 50% to 65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy
III. Repolarization abnormalities
Major
Inverted T waves in right precordial leads (V1, V2, and V3) or beyond in individuals >14 years of age (in the absence of complete right bundle-branch block QRS ≥120 ms)
Minor
Inverted T waves in right precordial leads (V2 and V3) (people age >12 years, in absence of right bundle-branch block)
Inverted T waves in leads V1 and V2 in individuals >14 years of age (in the absence of complete right bundle-branch block) or in V4, V5, or V6
Inverted T waves in leads V1, V2, V3, and V4 in individuals >14 years of age in the presence of complete right bundle-branch block
IV. Depolarization/conduction abnormalities
Major
Epsilon waves or localized prolongation (>110 ms) of the QRS complex in right precordial leads (V1 to V3)
Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T wave) in the right precordial leads (V1 to V3)
Minor
Late potentials (SAECG)
Late potentials by SAECG in ≥1 of 3 parameters in the absence of a QRS duration of ≥110 ms on the standard ECG
Filtered QRS duration (fQRS) ≥114 ms
Duration of terminal QRS <40 µV (low-amplitude signal duration) ≥38 ms
Root-mean-square voltage of terminal 40 ms ≤20 µV
Terminal activation duration of QRS ≥55 ms measured from the nadir of the S wave to the end of the QRS, including R´, in V1, V2, or V3, in the absence of complete right bundle-branch block
V. Arrhythmias
Major
Nonsustained or sustained ventricular tachycardia of left bundle-branch morphology with superior axis (negative or indeterminate QRS in leads II, III, and aVF and positive in lead aVL)
Minor
Left bundle-branch block–type ventricular tachycardia (sustained and nonsustained) (ECG, Holter, exercise)
Frequent ventricular extrasystoles (>1000 per 24 hours) (Holter)
Nonsustained or sustained ventricular tachycardia of RV outflow configuration, left bundle-branch block morphology with inferior axis (positive QRS in leads II, III, and aVF and negative in lead aVL) or of unknown axis
>500 ventricular extrasystoles per 24 hours (Holter)
VI. Family history
Major
Familial disease confirmed at necropsy or surgery
ARVC/D confirmed in a first-degree relative who meets current Task Force criteria
ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
Identification of a pathogenic mutation† categorized as associated or probably associated with ARVC/D in the patient under evaluation
Minor
Family history of premature sudden death (<35 years of age) due to suspected ARVC/D
Familial history (clinical diagnosis based on present criteria)
History of ARVC/D in a first-degree relative in whom it is not possible or practical to determine whether the family member meets current Task Force criteria
Premature sudden death (<35 years of age) due to suspected ARVC/D in a first-degree relative
ARVC/D confirmed pathologically or by current Task Force Criteria in second-degree relative
PLAX indicates parasternal long-axis view; RVOT, RV outflow tract; BSA, body surface area; PSAX, parasternal short-axis view; aVF, augmented voltage unipolar left foot lead; and aVL, augmented voltage unipolar left arm lead.
Diagnostic terminology for original criteria: This diagnosis is fulfilled by the presence of 2 major, or 1 major plus 2 minor criteria or 4 minor criteria from different groups. Diagnostic terminology for revised criteria: definite diagnosis: 2 major or 1 major and 2 minor criteria or 4 minor from different categories; borderline: 1 major and 1 minor or 3 minor criteria from different categories; possible: 1 major or 2 minor criteria from different categories.
∗ Hypokinesis is not included in this or subsequent definitions of RV regional wall motion abnormalities for the proposed modified criteria.
† A pathogenic mutation is a DNA alteration associated with ARVC/D that alters or is expected to alter the encoded protein, is unobserved or rare in a large non–ARVC/D control population, and either alters or is predicted to alter the structure or function of the protein or has demonstrated linkage to the disease phenotype in a conclusive pedigree.
